These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 35457259)

  • 1. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
    Arisi MF; Dotan E; Fernandez SV
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
    Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
    Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
    Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
    Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
    J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
    Nakamura Y; Yoshino T
    Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
    Bent A; Raghavan S; Dasari A; Kopetz S
    Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
    Haupts A; Roth W; Hartmann N
    Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
    Malla M; Loree JM; Kasi PM; Parikh AR
    J Clin Oncol; 2022 Aug; 40(24):2846-2857. PubMed ID: 35839443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
    Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
    Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.
    Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
    Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
    Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
    Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer.
    Malla M; Parikh AR
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):583-601. PubMed ID: 35577710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
    Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
    Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling.
    Yaegashi M; Iwaya T; Sasaki N; Fujita M; Ju Z; Siwak D; Hachiya T; Sato K; Endo F; Kimura T; Otsuka K; Sugimoto R; Sugai T; Liotta L; Lu Y; Mills GB; Nakagawa H; Nishizuka SS
    Br J Cancer; 2021 Apr; 124(9):1556-1565. PubMed ID: 33658639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.